Lilly Q2 EPS $1.05 ($1.25 non-GAAP); revenue down 4% to $6.49B; key growth products up 20%

ELI LILLY & Co

2022-Q2 EPS reported $3.16 revenue$14,298,000,000

Revenue $6,488M (-4% YoY; -1% constant currency); core revenue up 6% excluding Alimta, Cialis rights sale, COVID antibodies.
Reported EPS $1.05 (-31%); non-GAAP EPS $1.25 (-32%); both include $0.46 acquired IPR&D charges.
Key growth products (Trulicity, Verzenio, Jardiance etc.) grew 20% to 67% of revenue (ex COVID antibodies).
2022 guidance: reported EPS $6.96-$7.11, non-GAAP $7.90-$8.05; revenue guidance unchanged.
FDA accepted donanemab (Alzheimer's) and pirtobrutinib (MCL) with Priority Review; Mounjaro approved for T2D; Olumiant for alopecia areata.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.